Daniel P. Radin

603 total citations
37 papers, 452 citations indexed

About

Daniel P. Radin is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Genetics. According to data from OpenAlex, Daniel P. Radin has authored 37 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 19 papers in Cellular and Molecular Neuroscience and 7 papers in Genetics. Recurrent topics in Daniel P. Radin's work include Neuroscience and Neuropharmacology Research (14 papers), Receptor Mechanisms and Signaling (8 papers) and Glioma Diagnosis and Treatment (7 papers). Daniel P. Radin is often cited by papers focused on Neuroscience and Neuropharmacology Research (14 papers), Receptor Mechanisms and Signaling (8 papers) and Glioma Diagnosis and Treatment (7 papers). Daniel P. Radin collaborates with scholars based in United States, Slovenia and United Kingdom. Daniel P. Radin's co-authors include Stella E. Tsirka, Arnold Lippa, Parth Patel, Sheng Zhong, Rok Cerne, Jeffrey M. Witkin, Steve A. Johnson, Varun Kumar, Gregory T. Smith and Gary A. Rogers and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Daniel P. Radin

35 papers receiving 438 citations

Peers

Daniel P. Radin
Daniel Ye United States
Paola Spinsanti Italy
Mark Morris United States
John H. Stockley United Kingdom
Katrin Trautmann Germany
Alison Todd Australia
Daniel Ye United States
Daniel P. Radin
Citations per year, relative to Daniel P. Radin Daniel P. Radin (= 1×) peers Daniel Ye

Countries citing papers authored by Daniel P. Radin

Since Specialization
Citations

This map shows the geographic impact of Daniel P. Radin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel P. Radin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel P. Radin more than expected).

Fields of papers citing papers by Daniel P. Radin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel P. Radin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel P. Radin. The network helps show where Daniel P. Radin may publish in the future.

Co-authorship network of co-authors of Daniel P. Radin

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel P. Radin. A scholar is included among the top collaborators of Daniel P. Radin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel P. Radin. Daniel P. Radin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Radin, Daniel P., Rok Cerne, Jodi L. Smith, Jeffrey M. Witkin, & Arnold Lippa. (2025). Antipsychotic-like pharmacological profile of the low impact ampakine CX691 (farampator): Implications for the use of low impact ampakines in the treatment of schizophrenia. Journal of Psychiatric Research. 186. 145–153. 1 indexed citations
2.
Smith, Jodi L., et al.. (2025). Is there a continued need for behavioral pharmacology in the discovery and development of medicines?. Journal of Pharmacology and Experimental Therapeutics. 392(5). 103571–103571.
3.
Radin, Daniel P., Sheng Zhong, Rok Cerne, et al.. (2025). Preclinical Pharmacology of CX1837, a High-Impact Ampakine with an Improved Safety Margin: Implications for Treating Alzheimer’s Disease and Ischemic Stroke. Current Alzheimer Research. 21(10). 745–754.
4.
Radin, Daniel P., Rok Cerne, Jodi L. Smith, Jeffrey M. Witkin, & Arnold Lippa. (2025). Safety, tolerability and pharmacokinetic profile of the low-impact ampakine CX717 in young healthy male subjects and elderly healthy male and female subjects. European Journal of Pharmacology. 993. 177317–177317. 3 indexed citations
5.
Witkin, Jeffrey M., Daniel P. Radin, Sabhya Rana, et al.. (2024). AMPA receptors play an important role in the biological consequences of spinal cord injury: Implications for AMPA receptor modulators for therapeutic benefit. Biochemical Pharmacology. 228. 116302–116302. 7 indexed citations
6.
Radin, Daniel P., Sheng Zhong, Rok Cerne, et al.. (2024). Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents. SHILAP Revista de lepidopterología. 4(1). 173–187. 12 indexed citations
7.
Radin, Daniel P., Rok Cerne, Jeffrey M. Witkin, & Arnold Lippa. (2024). High-Impact AMPAkines Elevate Calcium Levels in Cortical Astrocytes by Mobilizing Endoplasmic Reticular Calcium Stores. SHILAP Revista de lepidopterología. 5(3). 344–355. 1 indexed citations
8.
Rana, Sabhya, Jeffrey M. Witkin, Daniel P. Radin, et al.. (2024). Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy. Pharmacology & Therapeutics. 265. 108744–108744. 3 indexed citations
9.
Radin, Daniel P., Sheng Zhong, Rok Cerne, Jeffrey M. Witkin, & Arnold Lippa. (2024). High Impact AMPAkines Induce a Gq‐Protein Coupled Endoplasmic Calcium Release in Cortical Neurons: A Possible Mechanism for Explaining the Toxicity of High Impact AMPAkines. Synapse. 78(5). e22310–e22310. 1 indexed citations
10.
Smith, Gregory T., Daniel P. Radin, & Stella E. Tsirka. (2022). From protein-protein interactions to immune modulation: Therapeutic prospects of targeting Neuropilin-1 in high-grade glioma. Frontiers in Immunology. 13. 958620–958620. 8 indexed citations
11.
Radin, Daniel P., et al.. (2022). Lucanthone Targets Lysosomes to Perturb Glioma Proliferation, Chemoresistance and Stemness, and Slows Tumor Growth In Vivo. Frontiers in Oncology. 12. 852940–852940. 14 indexed citations
12.
Radin, Daniel P., et al.. (2019). PINK1 depletion sensitizes non-small cell lung cancer to glycolytic inhibitor 3-bromopyruvate: Involvement of ROS and mitophagy. Pharmacological Reports. 71(6). 1184–1189. 33 indexed citations
13.
Radin, Daniel P., et al.. (2018). Ampakines Attenuate Staurosporine-induced Cell Death in Primary Cortical Neurons: Implications in the ‘Chemo-Brain’ Phenomenon. Anticancer Research. 38(6). 3461–3465. 8 indexed citations
14.
Radin, Daniel P., et al.. (2018). Oncolytic Properties of Ampakines In Vitro. Anticancer Research. 38(1). 265–269. 10 indexed citations
15.
Radin, Daniel P., et al.. (2018). Stargazin differentially modulates ampakine gating kinetics and pharmacology. Biochemical Pharmacology. 148. 308–314. 4 indexed citations
16.
Radin, Daniel P., et al.. (2018). Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain. Biomedicine & Pharmacotherapy. 105. 540–544. 22 indexed citations
17.
Radin, Daniel P., et al.. (2017). BDNF: An Oncogene or Tumor Suppressor?. Anticancer Research. 37(8). 3983–3990. 50 indexed citations
18.
Radin, Daniel P. & Parth Patel. (2017). A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake inhibitors. Biomedicine & Pharmacotherapy. 87. 636–639. 21 indexed citations
19.
Kim, Dongyeon, et al.. (2017). Probing the Molecular Mechanisms Governing the Oncolytic Activity of Paeonia suffruticosa on Triple-negative Breast Cancer Cells In Vitro. Anticancer Research. 37(9). 4813–4819. 3 indexed citations
20.
Radin, Daniel P., et al.. (2016). Delineating the molecular mechanisms of tamoxifen’s oncolytic actions in estrogen receptor-negative cancers. European Journal of Pharmacology. 781. 173–180. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Ye Breakdown of academic impact, for papers by Paola Spinsanti Breakdown of academic impact, for papers by Mark Morris Breakdown of academic impact, for papers by John H. Stockley Breakdown of academic impact, for papers by Katrin Trautmann Breakdown of academic impact, for papers by Alison Todd
Rankless by CCL
2026